Sun Pharmaceutical Industries Limited (SUNPHARMA) — Financial Results | 22 May 2025(2 announcements)

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

Sun Pharmaceutical reported FY25 revenue of ₹520,412 crores, up 9.0% YoY, with net profit of ₹109,290 crores and adjusted net profit of ₹119,844 crores up 19.0%. The company proposed a final dividend of ₹5.50 per share, adding to prior dividends, totaling ₹16.00 per share for FY25. Key growth drivers included strong performance in India formulation (13.7% growth) and Global Specialty (17.1% growth), supported by R&D investment of ₹32,484 crores (6.2% of sales). The Board approved results highlighting market share gains in India (8.3% in a ₹2,259 billion market) and US formulation growth (3.6% YoY).

2 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

Sun Pharmaceutical reported consolidated net profit of ₹87.22 crores for Q4 FY25, a 32% year-on-year increase from ₹65.97 crores in Q4 FY24, driven by strong revenue growth to ₹1,150 crores (+18% YoY). The company highlighted improved operational efficiency and margin expansion as key drivers of profitability.

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUNPHARMA — Free

Free account · 2 AI queries/day